Free Newsletter
Researchers explore brain cancer vaccine
Researchers are touting the early results from a study of a new brain cancer vaccine that combines protein antigens extracted from a patient's tumor and matches them with white cells also drawn from the patient. The therapy is injected into patients, spurring T-cells to attack the remaining cancer cells after tumor-removal surgery. The vaccine, DCVax-Brain, is being developed by Bothell, WA-based Northwest Biotherapeutics.
"I've never seen a clinical trial that's had this promise," said Dr. Michael Gruber, medical director of the Brain Tumor Center of New Jersey.
- read the article from the Monterey Herald
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
